ArticleMolecular biology reports2026
Comparative multi-pathway inhibition of breast cancer by micro-and nano-formulated Curcumin.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
OBJECTIVES AND
backgroundBreast cancer (BC) remains a leading cause of cancer-related death among women. There is an urgent need for new therapies with fewer side effects. This study evaluated the anticancer potential of curcumin micro- and nanocapsules on MCF-7 breast cancer cells and explored the underlying molecular mechanisms using bioinformatics analysis. MATERIALS AND
methodsCurcumin micro- and nanocapsules were produced through mechanical encapsulation and tested on MCF-7 cells. Cell viability was measured by MTT assay, apoptosis and cell cycle changes were analyzed by flow cytometry, and gene expression of C-myc, Ki-67, EGFR, VEGFR2, and Caspase-3 was evaluated by real-time PCR. Public datasets (TCGA and CPTAC) were analyzed to identify curcumin-related genes, pathways, and drug-target networks.
resultsBoth formulations reduced cell viability by 45-60% and significantly increased apoptosis, with nanocapsules being more potent. Nanocapsules caused G2/M phase arrest and a 3.8-fold rise in Caspase-3 expression, while microcapsules mainly induced G0/G1 arrest. Treatments suppressed the proliferation markers C-myc and Ki-67, along with EGFR and VEGFR2. Bioinformatics analysis confirmed that these genes are key regulators in MAPK, PI3K/Akt, WNT, and HER2 pathways affected by curcumin.
conclusionNano-formulated curcumin demonstrates strong, multi-target anticancer activity by blocking cell growth and angiogenesis while promoting apoptosis. These findings support its potential as a safe and effective therapeutic option for breast cancer.
Indexed as
Identifiers
41721902What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.